PARIS and MARSEILLE, France, January 11 TheINSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of ascientific collaboration agreement in the breast cancer domain. Within theframework of this project, the current scientific knowledge on Ipsogen'sMapQuant Dx Grade Genomic, HER2 and HR tests will be increased thanks to newdata established from a large population of patients treated at the InstitutCurie. The aim of this collaboration is to evaluate these tests compared tocurrent breast cancer characterization techniques. Indeed, these new testscould represent, for oncologists and pathologists, helpful decision-makingtools enabling them to improve the diagnostic process and optimally adapttheir therapeutic strategy to each patient.
Within the framework of this collaboration, the genomic analysis of 200breast tumors will be performed on the Institut Curie's molecular diagnosticplatform, using the expertise of the Institut Curie, in particular thetranslational research department and clinical teams specialized in breastcancer, and Ipsogen.
Sergio Roman-Roman, Head of Translational Research at the Institut Curie,states: "the existence, at the Institut Curie, of a bank ofwell-characterized human tumor samples, as well as a particularly stronggenomic analysis platform, makes it possible to conduct a reliable assessmentof molecular diagnostic tools such as the one that is the subject of thiscollaboration. The stakes are high because these tools, once validated viaresearch such as those we are beginning today, can be a substantial aid tomaking therapeutic decisions for women with breast cancer."
Vincent Fert, CEO of Ipsogen, adds: "This first collaboration with theInstitut Curie is very important for our company, and reflects therecognition of the quality of our development work. By pooling thecomplementary scientific and clinical know-how of the Institut Curie and thetechnical and industrial know-how of Ipsogen, it will be possible to makefaster progress towards personalized medicine. It will also enable us, as wehave already successfully done in onco-hematology, to continue collaboratingwith oncologists to develop products that meet their clinical needs in breastcancer."
About the Institut Curie
The Institut Curie is a private non-profit foundation that combinesFrance's largest oncology research center and a state-of-the-art hospitalthat has pioneered many treatments. It is a reference center in breastcancer, tumors in children and adolescents and eye cancers, and disseminatesmedical innovations nationwide and worldwide.
Founded in 1909 on a model designed by Marie Curie and stillcutting-edge, "from basic research to innovative healthcare," the InstitutCurie has some 2,000 researchers, physicians and healthcare staff who allwork towards a common goal: to defeat cancer.
A vital link between clinicians and scientists, the Institut Curie'stranslational research department forms a bridge from research progress tohospitals and industry. This department's competence in genomics,post-genomics, immunomonitoring, pharmacology and biology complement theInstitut Curie's scientific and clinical activity.
IPSOGEN, Cancer Profiler, develops and markets molecular diagnostic teststhat help map diseases to guide oncologists and patients in their therapeuticdecisions.
Strengthened by its scientific and clinical partnerships with recognizedacademic centers, and its multidisciplinary teams in France and the USA, andwith more than 70 tests already used routinely worldwide for the diagnosis,prognosis and follow-up of thousands of patients with leukemia, Ipsogen isnow targeting breast cancer with the aim of providing currently inaccessiblediagnostic information.
Ipsogen employed 60 people as of June 30, 2009. Its headquarters arelocated in Marseille, France, with a subsidiary, Ipsogen Inc., in Stamford,CT, USA.
For more information, visit http://www.ipsogen.com
SOURCE Ipsogen SA